Jacinda Ardern
Associate Minister, Arts, Culture and Heritage
Minister, Child Poverty Reduction
Minister, Ministerial Services
Minister, National Security and Intelligence
Prime Minister
Permanent linkKia ora koutou. Good afternoon, everyone. First up today, I want to speak to the latest progress we’ve made in securing COVID medicines. As we settle into the new traffic light framework you’ll see that our COVID response remains one where we push forward cautiously with fewer restrictions, more careful travel around the country, and families and friends reuniting. COVID treatments are an important part of this momentum and provide an extra layer of protection to keep people safe as those restrictions are eased.
Today, I can announce that Pharmac has signed an advance purchase agreement for 60,000 courses of Pfizer’s oral antiviral treatment, which is now subject to Medsafe approval. While only early and interim data has been released, clinical trials have shown this treatment is shaping up to be particularly promising, with an 89 percent reduction in hospitalisation and death. In simple terms, this drug taken orally over the course of a few days is the first of its kind to really home in on coronavirus and can be taken at the first sign of symptoms to help stop people from getting really unwell. It’s a big step forward for the management of COVID-19 globally. I know many of you may be interested in some of the clinical trials and other elements of this purchase, so Dr Bloomfield, Dr Ian Town, and Sarah Fitt from Pharmac will be providing a briefing at the end of this week. That will also be live streamed.
This is our second advance purchase agreement for an oral antiviral to treat mild to moderate cases of COVID-19 with an agreement for 60,000 courses of molnupiravir signed in October, and that brings our suite of COVID medicines secured and managed by Pharmac to six in total, three of which are already in use in our hospitals and the rest of which, subject to Medsafe approval, will arrive in New Zealand early in the New Year.
Alongside vaccinations, our hospital treatments are already reducing the likelihood of people needing ICU care, and for a range of factors the ICU rate in Auckland has dropped to 3 percent of hospitalisations, down from the 5.7 percent that we saw earlier on in the pandemic. We’ve made sure Pharmac can continue to secure early access to new and promising COVID medicines as soon as possible, with $175 million allocated for medicines and supply chain costs and another $300 million available for purchasing more COVID-19 therapeutics.
Treatments are only one part of our plan. We must continue with all the other elements of our strategy to manage COVID-19, like, for instance, contact tracing and testing, and here’s another good reason why. Pfizer’s new antiviral has a three- to five-day window from the beginning of COVID symptoms to be effective, most effective from three days but still with efficacy up to five. So while the drug will work for people early on in their illness, they may have already been sick for a day or two, which is why we need to maintain an effective contact tracing, testing, and clinical assessment regime to make sure that we reach people in a timely way so these drugs can really have their full benefit. But, of course, preventing people from getting COVID in the first place, through vaccination and safety nets built into the traffic light system, is still the very best protection we can offer. We don’t want to wait until people are well and then treat them.
Per capita, New Zealand maintains the lowest number of cases and deaths in the OECD and they’re well below other countries too. Our total case numbers sit at a total of about 12,000, the lowest in all of the 38 countries of the OECD. Next up is Iceland at 18,000, 90,000 in Luxembourg, and then all other countries come in at hundreds of thousands then millions, peaking at nearly 50 million in the US. On deaths, well of course every single one of our 44 deaths is obviously an absolute tragedy that we would rather have prevented. So too are the 880 in Luxenberg, the 2,000 in Australia, and the 788,000 in the United States.
And even right down to the local level, we see the success of our cautious approach. In the past week across the northern DHBs, which include the three Auckland DHBs and Northland, there were 432 fewer cases and 70 fewer hospitalisations than has been projected. That demonstrates that vaccines are working, but we know, with the transmissibility of Delta, that we will have more cases in our communities and more people recovering at home, and so we must be as prepared as possible to support all of those individuals to get well soon. And so treatments are another way we can keep people safe and ensure that our hospitals maintain capacity.
Finally, an update on vaccination projections. As we move forward and look to review the traffic lights on Monday, 13 December and the Auckland boundary eases on Wednesday, 15 December, we move forward as a highly vaccinated population—88 percent of our eligible population is now fully vaccinated, and 93 percent have their first dose. We’ve some new projections that I want to share today. As a nation we are projected to hit 90 percent double dose on 14 or 15 December, as the Auckland boundary changes. All Auckland DHBs are projected to hit 90 percent by 15 December also.
My message, finally, then, is simple. We are in a system that relies on a good spread of vaccination, and we have achieved that. But every percentage point helps, which means every vaccination helps. So if you’re due for your second dose, please get it this week. If you haven’t yet had your first, please talk to someone who has, reach out, make sure you’re having your questions answered. It’s the number one thing you can do to help make sure we have a safe Christmas and summer for you and your loved ones. We’re happy now to take questions.